OBT and Boehringer Ingelheim Enter Collaboration
News Apr 29, 2013
Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) have announced a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.
Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications.
Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.
OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.
Christian Rohlff, CEO of OBT, commented: “Selecting the right target is fundamental for the successful development of a first-in-class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development.”
Shedding Light on How Tumors Become Resistant to ImmunotherapyNews
Researchers have now found that in skin cutaneous melanoma an epigenetic control protein is key to the development of immunotherapy resistance.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Nanoparticle Delivery of Curcumin Induces Tumor Cell DeathNews
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cellsREAD MORE